Kala Bio Inc (KALA) Stock Price, Quote & News

Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 996 5252

Fax: 781 642 0399

Website: www.kalarx.com

Address:

1167 Massachusetts Avenue, Arlington, United States

Stockswingalert Sep. 12 at 2:03 AM

$KALA 258% Told you bio red hot 🔥🔥🔥🔥

0 · Reply

Luv2trade2 Sep. 11 at 11:29 PM

$KALA where did you find this?

1 · Reply

faz999 Sep. 11 at 9:50 PM

$KALA another hedge Taking 7% wow Crazy like I said they know something that KALA approval then buyout of KALA after approval Drug sales over 1Bil minimum $100 EPS Buyer Point72 Capital Advisors, In 469k

0 · Reply

faz999 Sep. 11 at 9:16 PM

$KALA wow another hedge brought 543k with 7% ownership Just getting better and better this only means one thing KALA going up with potential huge upside New buyer Joseph Edelman is the Chief Executive Officer and founder of Perceptive Advisors LLC, a New York City-based hedge fund that specializes in biotechnology stocks, which he founded in 1999 with the goal of supporting progress in the life sciences industry by identifying opportunities and directing financial resources

0 · Reply

FloBerg Sep. 11 at 2:24 PM

$KALA NXXT sentiment shifting bullish social chatter rising along with steady bids early adopter crowd riding the wave 📣

1 · Reply

anachartanalyst Sep. 11 at 2:03 PM

$KALA https://anachart.com/wp-content/uploads/ana_temp/1757599311_soc-img.jpg

0 · Reply

faz999 Sep. 11 at 1:47 PM

$KALA Analyst aligned them self so they do not look like they were behind the curve. Hedges took position earlier in the year knowing well this can reached $100 on approval. Which still be undervalued as very low float. Time to sit back wait until approval.

1 · Reply

DARKP00L Sep. 11 at 1:33 PM

$KALA 09:29 on Sep. 11 2025 Oppenheimer Maintains Outperform on Kala Bio, Raises Price Target to $33 #tradeideas

0 · Reply

JarvisFlow Sep. 11 at 1:30 PM

Oppenheimer has adjusted their stance on Kala Bio ( $KALA ), setting the rating to Outperform with a target price of 15 → 33.

0 · Reply

faz999 Sep. 10 at 3:54 PM

$KALA don't be surprise when data is released PPS can hit $40 any given day. Hold on for full approval I think it can hit $100 with potential sale of the drug @ 1 bil company valuation will only increase exponentially. I am in this to the end....

1 · Reply

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:00 AM EDT - 5 weeks ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 9, 2025, 8:00 AM EDT - 2 months ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

May 29, 2025, 8:00 AM EDT - 3 months ago

KALA BIO to Present at Jefferies Global Healthcare Conference

Feb 12, 2025, 8:00 AM EST - 7 months ago

KALA BIO Announces Chief Executive Officer Transition

Dec 30, 2024, 8:00 AM EST - 9 months ago

KALA BIO Announces $10,750,000 Private Placement

Nov 27, 2024, 8:00 AM EST - 10 months ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

May 14, 2024, 4:05 PM EDT - 1 year ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 1 year ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 26, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Jan 19, 2024, 4:01 PM EST - 1 year ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2023, 8:00 AM EST - 1 year ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 5, 2023, 8:00 AM EDT - 2 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 4, 2023, 8:00 AM EDT - 2 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 2, 2023, 4:01 PM EDT - 2 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Jul 19, 2023, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Mar 27, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 8, 2023, 4:01 PM EST - 2 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 3, 2023, 8:00 AM EST - 2 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Jan 19, 2023, 7:12 AM EST - 2 years ago

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

Dec 30, 2022, 12:02 PM EST - 2 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 29, 2022, 8:30 AM EST - 2 years ago

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Dec 28, 2022, 6:48 AM EST - 2 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 27, 2022, 4:01 PM EST - 2 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Nov 28, 2022, 4:02 PM EST - 3 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 8, 2022, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 1, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Sep 6, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 19, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 18, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 12, 2022, 7:51 PM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call Transcript

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 11, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jun 2, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

May 23, 2022, 10:17 AM EDT - 3 years ago

Why Kala Pharmaceuticals Shares Are Rising Today

May 23, 2022, 12:01 AM EDT - 3 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 16, 2022, 10:54 AM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

May 16, 2022, 7:00 AM EDT - 3 years ago

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

May 2, 2022, 1:25 PM EDT - 3 years ago

Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

May 1, 2022, 9:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Apr 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting

Mar 29, 2022, 12:10 PM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2021 Results - Earnings Call Transcript

Mar 29, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Stockswingalert Sep. 12 at 2:03 AM

$KALA 258% Told you bio red hot 🔥🔥🔥🔥

0 · Reply

Luv2trade2 Sep. 11 at 11:29 PM

$KALA where did you find this?

1 · Reply

faz999 Sep. 11 at 9:50 PM

0 · Reply

faz999 Sep. 11 at 9:16 PM

0 · Reply

FloBerg Sep. 11 at 2:24 PM

$KALA NXXT sentiment shifting bullish social chatter rising along with steady bids early adopter crowd riding the wave 📣

1 · Reply

anachartanalyst Sep. 11 at 2:03 PM

$KALA https://anachart.com/wp-content/uploads/ana_temp/1757599311_soc-img.jpg

0 · Reply

faz999 Sep. 11 at 1:47 PM

1 · Reply

DARKP00L Sep. 11 at 1:33 PM

$KALA 09:29 on Sep. 11 2025 Oppenheimer Maintains Outperform on Kala Bio, Raises Price Target to $33 #tradeideas

0 · Reply

JarvisFlow Sep. 11 at 1:30 PM

Oppenheimer has adjusted their stance on Kala Bio ( $KALA ), setting the rating to Outperform with a target price of 15 → 33.

0 · Reply

faz999 Sep. 10 at 3:54 PM

1 · Reply

KeriKocon133 Sep. 10 at 4:18 AM

Watchlist 🎯 $KAPA $ONDS $KALA $JMIA $TAIT Also keep MITQ on high watch, this is setting up to be the next super stock in small caps

0 · Reply

Drive2 Sep. 9 at 4:51 PM

$KALA meeting w piper sandler today and tomorrow is another HC Wainwright investor presentation. I don't expect anything different but could it be

2 · Reply

ExecutiveEdge Sep. 9 at 1:12 AM

I called OCTO to a tee check this photo 🔽⏬🔽 Now I am calling 🚨MSS🚨 this can easily 5x, they are profitable with no company selling and strong insider ownership $NBY $AGH $KALA $BMNR

1 · Reply

Eissalon Sep. 8 at 5:43 PM

$KALA $CRNX $PRSO $NDLS $NVCR Sleeping boys (and girls) catch no fish, ..soon, hot🔥 NVCR, CEO 1M buy at market, sentiment swing potential NDLS, Sale/refranchising/debt refi optionality PRSO, board response or bidder escalation forces tape CRNX, Late‑stage, oral endocrine therapy, IV rise KALA, Small‑cap data pop/flush setup SMTK ?? risky!! micro, Any partner/bid = outsized move, risks: Liquidity, no deal kisses😘

0 · Reply

Drive2 Sep. 8 at 5:02 PM

$KALA investors still asleep on this one

1 · Reply

JarvisFlow Sep. 8 at 12:00 PM

Mizuho has adjusted their stance on Kala Bio ( $KALA ), setting the rating to Outperform with a target price of 30.

1 · Reply

Thestocktraderhubzee Sep. 8 at 11:46 AM

$KALA Mizuho Initiates Coverage On Kala Bio with Outperform Rating, Announces Price Target of $30

0 · Reply

StockChronicals Sep. 7 at 11:23 PM

$KALA swing

0 · Reply

DARKP00L Sep. 5 at 5:46 PM

$KALA this stock is attracting a lot of interest. Be prepared for possible changes!

0 · Reply

JazsminC Sep. 5 at 2:28 PM

$KALA Consolidation, then move higher.

0 · Reply

Drive2 Sep. 4 at 8:30 PM

$KALA My attempts to value this company (pending strong results of phase 2) - I think the only place to turn to is Oxervate. But they are a private Italian company named Dompe. So let's say they were public with sales of $1.2B. What would wall street value them at? 3x sales? $3B+ Point being KALA is still massively undervalued at $100 million. At $50 a share its only a $350 million company w a sales potential of $3B. I don't know and this is pointless anyway if results aren't strong lol

1 · Reply

Bazzzigar Sep. 4 at 6:18 PM

$KALA RXRX

0 · Reply

Market Cap	107.21M
Revenue (ttm)	0.00
Net Income (ttm)	-38.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-10.32

Volume	338,200
Avg Vol	203,078
Day's Range	N/A - N/A
Shares Out	7.02M
Stochastic %K	97%
Beta	-1.81
Analysts	Strong Sell
Price Target	$21.00